Aimovig (erenumab-aooe) is a once-monthly, self-administered injection used to prevent migraines in adults. It helps prevent migraines before they start and reduces the number of migraine days per month.
Table of Contents
What is Aimovig?
Aimovig (erenumab-aooe) is the first FDA-approved CGRP monoclonal antibody for preventing migraines in adults. Unlike acute treatments, it’s a monthly self-injected therapy that blocks calcitonin gene-related peptide (CGRP), a key migraine-triggering molecule.
How Aimovig Works
Migraines involve CGRP-driven inflammation and pain signaling. Aimovig works by:
- Binding to CGRP receptors, preventing activation.
- Reducing nerve inflammation in trigeminal pathways.
- Cutting monthly migraine days within 1-3 months.
Clinical Impact:
- 50%+ patients achieve ≥50% reduction in migraine frequency.
- Effects sustained for 3+ years in long-term studies.
Aimovig Dosage & Administration
| Dosage | Form | Frequency | Best For |
|---|---|---|---|
| 70 mg | Auto-injector pen | Once monthly | New users |
| 140 mg | Auto-injector pen | Once monthly | Inadequate 70mg response |
Self-Injection Tips:
- Rotate sites (thigh, abdomen, upper arm).
- Allow 30 mins for refrigerated pen to warm.
- Use alcohol swabs to clean skin pre-injection.
Aimovig Side Effects
Common (≥5% Users):
- Injection site reactions (redness/swelling)
- Constipation (manage with hydration/fiber)
- Muscle cramps
- Fatigue
Rare but Serious:
- Severe constipation (requiring hospitalization)
- Hypertension (monitor BP monthly)
- Hypersensitivity (rash, anaphylaxis)
Aimovig Effectiveness
Episodic Migraines (4-14 migraine days/month):
- Avg. 3.2-4.7 fewer migraine days/month vs placebo.
Chronic Migraines (15+ headache days/month):
- Avg. 6.6 fewer migraine days/month in 50% of patients.
Real-World Evidence:
- 68% report improved quality of life (2023 JAMA study).
- 42% reduce acute medication use.
Aimovig Cost & Savings Programs
| Country | Monthly Cost | Insurance Coverage |
|---|---|---|
| USA | $650-$750 | Most private plans |
| UK | £320 (NHS) | Fully covered |
| Canada | CAD$615 | Provincial plans |
| India | ₹58,000 | Limited private insurance |
Savings Programs:
- Aimovig Ally™: $0 copay for commercially insured (USA).
- Novartis Patient Assistance: Free doses for uninsured/low-income.
Aimovig vs. Other CGRP Inhibitors
| Drug | Dosing | Key Advantage | Cost vs. Aimovig |
|---|---|---|---|
| Aimovig | Monthly | First to market | $$ |
| Ajovy | Monthly/Quarterly | Flexible dosing | $ (5% cheaper) |
| Emgality | Monthly | Also treats cluster HA | $$ |
| Vyepti | Quarterly IV | Clinic-administered | $$$ |
Who Should Avoid Aimovig?
- History of CGRP antibody allergy.
- Pregnant/breastfeeding women (limited safety data).
- Severe gastrointestinal disorders (Crohn’s, chronic constipation).
- Uncontrolled hypertension.
Aimovig and Pregnancy: Critical Facts
- Animal studies: No fetal harm, but human data lacking.
- FDA Pregnancy Category: Not assigned (use only if benefits > risks).
- Breastfeeding: Erenumab detected in milk—avoid or discontinue.
Conclusion
Aimovig is a transformative option for migraine prevention, particularly if:
- You have ≥4 migraine days/month.
- Traditional preventives failed.
- Cost savings programs make it accessible.
Ready to try Aimovig?
➊ Ask your neurologist for a sample.
➋ Use the Aimovig Ally Savings Card.
➌ Track migraine days in a diary pre/post treatment.
